Tyrphostin_NN
AG-490_NN
inhibits_VBZ
cytokine-mediated_JJ
JAK3\/STAT5a\/b_NN
signal_NN
transduction_NN
and_CC
cellular_JJ
proliferation_NN
of_IN
antigen-activated_JJ
human_JJ
T_NN
cells_NNS
._.

Janus_NN
kinase_NN
3_CD
-LRB-_-LRB-
JAK3_NN
-RRB-_-RRB-
is_VBZ
a_DT
cytoplasmic_JJ
tyrosine_NN
kinase_NN
required_VBN
for_IN
T_NN
cell_NN
development_NN
and_CC
activated_VBN
by_IN
cytokines_NNS
that_WDT
utilize_VBP
the_DT
interleukin-2_NN
-LRB-_-LRB-
IL-2_NN
-RRB-_-RRB-
receptor_NN
common_JJ
gamma_NN
chain_NN
-LRB-_-LRB-
gamma_NN
-LRB-_-LRB-
c_NN
-RRB-_-RRB-
-RRB-_-RRB-
._.

Genetic_JJ
inactivation_NN
of_IN
JAK3_NN
is_VBZ
manifested_VBN
as_IN
severe_JJ
combined_JJ
immunodeficiency_NN
disease_NN
-LRB-_-LRB-
SCID_NN
-RRB-_-RRB-
in_IN
humans_NNS
and_CC
mice_NNS
._.

These_DT
findings_NNS
have_VBP
suggested_VBN
that_IN
JAK3_NN
represents_VBZ
a_DT
pharmacological_JJ
target_NN
to_TO
control_VB
certain_JJ
lymphoid-derived_JJ
diseases_NNS
._.

Here_RB
we_PRP
provide_VBP
novel_JJ
evidence_NN
that_IN
AG-490_NN
potently_RB
inhibits_VBZ
the_DT
autokinase_NN
activity_NN
of_IN
JAK3_NN
and_CC
tyrosine_NN
phosphorylation_NN
and_CC
DNA_NN
binding_NN
of_IN
signal_NN
transducer_NN
and_CC
activator_NN
of_IN
transcription_NN
5a_NN
and_CC
5b_NN
-LRB-_-LRB-
STAT5a\/b_NN
-RRB-_-RRB-
._.

Similar_JJ
inhibitory_JJ
effects_NNS
were_VBD
observed_VBN
with_IN
other_JJ
cytokines_NNS
that_WDT
use_VBP
gamma_NN
-LRB-_-LRB-
c_NN
-RRB-_-RRB-
._.

AG-490_NN
also_RB
inhibited_VBN
IL-2-mediated_JJ
proliferative_JJ
growth_NN
in_IN
human_JJ
T_NN
cells_NNS
with_IN
an_DT
IC50_NN
-RRB-_-RRB-
=_VBD
25_CD
microM_NN
that_WDT
was_VBD
partially_RB
recoverable_JJ
._.

Moreover_RB
,_,
we_PRP
demonstrate_VBP
that_IN
this_DT
inhibitor_NN
prevented_VBD
tetanus_NN
toxoid_NN
antigen-specific_JJ
T_NN
cell_NN
proliferation_NN
and_CC
expansion_NN
but_CC
failed_VBD
to_TO
block_VB
activation_NN
of_IN
Zap70_NN
or_CC
p56Lck_NN
after_IN
anti-CD3_JJ
stimulation_NN
of_IN
human_JJ
T_NN
cells_NNS
._.

Taken_VBN
together_RB
,_,
these_DT
findings_NNS
suggest_VBP
that_IN
AG-490_NN
inhibits_VBZ
the_DT
JAK3-mediated_JJ
Type_NN
II_CD
signaling_NN
pathway_NN
but_CC
not_RB
the_DT
T_NN
cell_NN
receptor-derived_JJ
Type_NN
I_NN
pathway_NN
and_CC
possesses_VBZ
therapeutic_JJ
potential_NN
for_IN
T_NN
cell-derived_JJ
pathologies_NNS
such_JJ
as_IN
graft-versus-host_JJ
disease_NN
,_,
allergy_NN
,_,
and_CC
autoimmune_JJ
disorders_NNS
._.

